Cadrenal Therapeutics, Inc. Common Stock
$1.12
$0.04 (+3.70%)
$1.08Day Range$1.14
Key Statistics
Market Cap
$3.85M
Shares Outstanding
3.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 20, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$1.10
Day High
$1.14
Day Low
$1.08
Volume
44.9K
VWAP
$1.10
Prev Close
$1.08
Transactions
--
Acc. Volume
--
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
PHARMACEUTICAL PREPARATIONSSIC 28345 employees822 A1A NORTH, PONTE VEDRA, FL, 32082904-300-0701IPO Jan 20, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001937993
- Composite FIGI
- BBG019STRT20
- Share Class FIGI
- BBG019STRT39
- Ticker Root
- CVKD
- SIC Code
- 2834
About Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock
Cadrenal Therapeutics, Inc. Common Stock (CVKD) closed the 2026-09-17 session at $1.12, up 3.70% versus the previous close (+0.04). The stock opened at $1.10 and traded between $1.08 and $1.14 during that session. Session trading volume was 45K shares. The volume-weighted average price (VWAP) is $1.10.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Cadrenal Therapeutics, Inc. Common Stock has a market capitalization of $3.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CVKD is listed on the XNAS exchange. The company employs approximately 5 people. Cadrenal Therapeutics, Inc. Common Stock is headquartered in PONTE VEDRA, FL. The recorded listing date is 2023-01-20.
On this page you can find market CVKD stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.